Perceptive Advisors LLC boosted its position in shares of Myokardia Inc (NASDAQ:MYOK) by 29.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 710,726 shares of the biotechnology company’s stock after buying an additional 160,009 shares during the quarter. Myokardia accounts for approximately 1.0% of Perceptive Advisors LLC’s investment portfolio, making the stock its 24th largest position. Perceptive Advisors LLC owned 1.99% of Myokardia worth $29,922,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of MYOK. BlackRock Inc. boosted its stake in Myokardia by 37.2% during the fourth quarter. BlackRock Inc. now owns 1,920,651 shares of the biotechnology company’s stock worth $80,859,000 after buying an additional 521,031 shares during the period. Farallon Capital Management LLC lifted its position in shares of Myokardia by 117.3% during the fourth quarter. Farallon Capital Management LLC now owns 863,732 shares of the biotechnology company’s stock worth $36,363,000 after purchasing an additional 466,232 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after purchasing an additional 398,900 shares during the last quarter. VHCP Management II LLC bought a new stake in shares of Myokardia during the third quarter worth $11,355,000. Finally, RTW Investments LP bought a new stake in shares of Myokardia during the third quarter worth $10,882,000. 83.91% of the stock is owned by institutional investors.
MYOK has been the subject of several research analyst reports. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. initiated coverage on Myokardia in a research report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 target price for the company. BidaskClub upgraded Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded Myokardia from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $60.00 target price on shares of Myokardia in a research report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $63.00.
Myokardia (NASDAQ:MYOK) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.20. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $5.63 million. Myokardia had a negative return on equity of 24.58% and a negative net margin of 204.48%. equities research analysts expect that Myokardia Inc will post -2 EPS for the current fiscal year.
In related news, Director Kevin P. Starr sold 816,326 shares of Myokardia stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anastasios Gianakakos sold 3,000 shares of Myokardia stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $41.09, for a total value of $123,270.00. Following the completion of the sale, the insider now owns 512,117 shares of the company’s stock, valued at $21,042,887.53. The disclosure for this sale can be found here. Insiders sold 848,326 shares of company stock valued at $35,859,872 over the last 90 days. 33.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Myokardia Inc (MYOK) Holdings Lifted by Perceptive Advisors LLC” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/12/myokardia-inc-myok-holdings-lifted-by-perceptive-advisors-llc.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.